Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC2185 | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7464.084 | 0.0090 | -0.9938 | 0.8152 | |
| HCC3153 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.000853 | uM | 7466.085 | 0.9341 | 0.8491 | 0.8684 | |
| HCC3153 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 7466.085 | 0.9450 | 0.8739 | 0.8684 | |
| HCC3153 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 7466.085 | 0.9566 | 0.9004 | 0.8684 | |
| HCC3153 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 7466.085 | 0.9848 | 0.9651 | 0.8684 | |
| HCC3153 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 7466.085 | 0.9975 | 0.9943 | 0.8684 | |
| HCC3153 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 7466.085 | 1.0194 | 1.0447 | 0.8684 | |
| HCC3153 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 7466.085 | 0.9908 | 0.9789 | 0.8684 | |
| HCC3153 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 7466.085 | 0.4034 | -0.2970 | 0.8684 | |
| HCC3153 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 7466.085 | 1.0903 | 1.2095 | 0.8684 | |
| HCC3153 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7467.084 | 0.9787 | 0.9673 | 1.3029 | |
| HCC3153 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7467.084 | 0.9663 | 0.9480 | 1.3029 | |
| HCC3153 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7467.084 | 0.9593 | 0.9373 | 1.3029 | |
| HCC3153 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7467.084 | 0.9394 | 0.9063 | 1.3029 | |
| HCC3153 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7467.084 | 0.9717 | 0.9564 | 1.3029 | |
| HCC3153 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7467.084 | 0.9894 | 0.9837 | 1.3029 | |
| HCC3153 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7467.084 | 0.9972 | 0.9956 | 1.3029 | |
| HCC3153 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7467.084 | 0.9660 | 0.9477 | 1.3029 | |
| HCC3153 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7467.084 | 0.2780 | -0.2513 | 1.3029 | |
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.000853 | uM | 7468.085 | 0.9061 | 0.8675 | 1.4385 | |
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 7468.085 | 0.9497 | 0.9296 | 1.4385 | |
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 7468.085 | 0.9291 | 0.9004 | 1.4385 | |
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 7468.085 | 0.9625 | 0.9475 | 1.4385 | |
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 7468.085 | 1.0223 | 1.0309 | 1.4385 | |
| HCC38 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 7468.085 | 1.0118 | 1.0163 | 1.4385 |